V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10286971 | 10042865 | 1.81 | 72.6 | null | 2022-04-02 | 2022-04-02 | Thalidomide 50mg | 02 | N | FLAIR TRIAL | 100949777 |
| 10288366 | 10042869 | 1.7 | 60.9 | Adjuvant (A) | 2019-09-02 | 2019-09-13 | ANAGRELIDE | 02 | N | IDELALISIB | 101746053 |
| 10288504 | 10042871 | 1.66 | 68 | Palliative (P) | 2018-09-17 | 2018-09-23 | RIALTO TRIAL | 02 | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100649716 |
| 10288877 | 10042872 | 0 | 91 | 03 | 2019-05-13 | 2019-05-13 | DHAP - R | 02 | N | CISPLATIN + DOXORUBICIN | 101845802 |
| 10289684 | 10042876 | 1.6 | 66.8 | 03 | 2020-05-13 | 2020-05-16 | Bexarotene | 02 | N | AFATINIB | 100710947 |
| 10289946 | 10042878 | 1.6 | 131 | null | 2018-07-22 | 2019-07-20 | IDELALISIB + RITUXIMAB | 02 | null | MELPHALAN | 100434061 |
| 10291890 | 10042882 | 1.63 | 68.2 | Palliative (P) | 2018-05-10 | 2018-05-10 | null | N | N | CAPECITABINE + RT | 101251735 |
| 10292499 | 10042883 | 1.69 | 78.7 | 03 | 2019-04-16 | 2019-05-06 | MELPHALAN | 02 | N | CISPLATIN + PEMETREXED | 101851387 |
| 10292516 | 10042884 | 1.64 | 56 | Palliative (P) | 2016-06-19 | 2016-06-21 | PRIMUS 002 TRIAL | 02 | N | IRINOTECAN + MDG | 101556712 |
| 10293224 | 10042885 | 1.85 | null | 03 | 2020-12-29 | 2020-12-29 | Radium 223 | 02 | N | BORTEZOMIB + MELPHALAN | 101745971 |
| 10293472 | 10042886 | 1.61 | 99 | Palliative (P) | 2020-10-21 | 2020-10-31 | Liposomal Doxorubicin 50mg/m2 | 02 | N | PACLITAXEL + TRASTUZUMAB | 101495777 |
| 10293663 | 10042887 | 1.89 | 82.8 | Palliative (P) | 2019-02-10 | 2019-02-14 | Oxaliplatin + Modified de Gramont | 02 | N | RIALTO TRIAL | 101641490 |
| 10294472 | 10042888 | 1.52 | 93 | Palliative (P) | null | 2018-07-06 | Bortezomib + MELPHALAN | N | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101787456 |
| 10294624 | 10042889 | 0 | 96.6 | Disease modification (D) | null | 2019-08-21 | Cetuximab 7 day (Cycle 1) | N | N | ACELARATE TRIAL | 100553261 |
| 10294801 | 10042890 | 1.75 | 84.8 | Neo-adjuvant (N) | 2019-08-31 | 2019-09-05 | CARBOPLATIN + EPIRUBICIN | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101299276 |
| 10294855 | 10042891 | 1.6 | 83.2 | Curative (C) | 2017-09-02 | 2017-09-08 | Bendamustine +/- Prednisolone | 02 | N | CYTARABINE + ETOPOSIDE | 100738994 |
| 10295025 | 10042893 | 1.69 | 72.5 | Palliative (P) | 2019-07-07 | 2019-07-10 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100366159 |
| 10295169 | 10042894 | 1.8 | 89 | Curative (C) | 2020-10-23 | 2020-10-23 | null | 02 | N | MELPHALAN + THALIDOMIDE | 100951311 |
| 10295481 | 10042895 | null | 0 | null | 2021-02-11 | 2021-02-11 | Paclitaxel+Trastuzumab wkly Maint | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL + TRASTUZUMAB | 101825217 |
| 10296135 | 10042896 | 1.71 | 79 | Curative (C) | null | 2019-06-18 | MPV | 01 | Y | NILOTINIB | 101021205 |
| 10296424 | 10042897 | null | 72.25 | null | 2021-08-26 | 2021-08-30 | Nilotinib | 02 | null | APALUTAMIDE | 100068559 |
| 10296487 | 10042898 | 1.73 | 70.5 | Palliative (P) | 2018-03-10 | 2018-03-13 | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 02 | null | ECX | 100596748 |
| 10296794 | 10042899 | 1.66 | 60.6 | Palliative (P) | 2018-11-13 | 2018-11-13 | Bortezomib + Daratumumab | 02 | N | OXALIPLATIN + MDG | 100794867 |
| 10297559 | 10042902 | 0 | 70.6 | null | 2019-05-23 | 2019-05-26 | OSIMERTINIB | 02 | null | MATRIX LYMPHOMA TRIAL | 100394923 |
| 10298237 | 10042905 | 1.6 | null | Palliative (P) | 2018-11-30 | 2018-12-19 | Doxorubicin 75mg/m2 | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100612908 |
| 10298241 | 10042906 | 1.56 | 67.8 | Adjuvant (A) | 2013-04-04 | 2018-05-29 | Atezolizumab | N | N | IRINOTECAN | 101248899 |
| 10298584 | 10042908 | 1.74 | 77 | 03 | 2021-11-24 | 2021-12-16 | GEMCARBO | 02 | null | STAMPEDE TRIAL | 101166478 |
| 10299069 | 10042909 | 0 | 72 | Curative (C) | 2016-10-30 | 2016-10-31 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 2 | N | DASATINIB | 101066390 |
| 10299345 | 10042911 | 1.67 | 75 | null | 2018-05-27 | 2018-05-29 | ABVD | N | N | CARBOPLATIN + CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 100047422 |
| 10299466 | 10042912 | 1.75 | 89.9 | Neo-adjuvant (N) | 2018-11-07 | 2018-11-10 | Temozolomide + RT | 02 | N | CISPLATIN + CAPECITABINE + EPIRUBICIN | 101121422 |
| 10299756 | 10042914 | 1.88 | 113 | Curative (C) | 2018-10-10 | 2018-10-16 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | N | OXALIPLATIN + RALTITREXED | 101632350 |
| 10300110 | 10042917 | 1.72 | 75.9 | null | 2019-06-01 | 2019-06-01 | ICE-R (Cycle 2 onwards) | 02 | null | CVD | 101070572 |
| 10301535 | 10042921 | 1.71 | 85.7 | 03 | 2017-06-30 | 2017-06-30 | MPT | 02 | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 100217492 |
| 10302282 | 10042922 | 1.65 | null | Neo-adjuvant (N) | 2018-03-12 | 2018-03-12 | EVEROLIMUS | N | N | LETROZOLE + RIBOCICLIB | 101319467 |
| 10302602 | 10042923 | null | 51 | Palliative (P) | 2018-12-31 | 2019-01-15 | Melphalan oral | 02 | N | BORTEZOMIB + DARATUMUMAB | 100733846 |
| 10303134 | 10042926 | 1.68 | 69.4 | Curative (C) | 2018-02-25 | 2018-03-06 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | OXALIPLATIN + MDG | 101768203 |
| 10303318 | 10042927 | 1.83 | 75 | null | 2021-11-24 | 2021-11-26 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | COMPARE TRIAL | 100167892 |
| 10304540 | 10042930 | 1.5 | 74 | Disease modification (D) | 2019-12-19 | 2019-12-29 | Liposomal Doxorubicin 50mg/m2 | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 101609384 |
| 10305682 | 10042933 | 1.82 | 96 | null | 2019-08-12 | 2019-08-12 | Vinorelbine (oral) | null | null | THALIDOMIDE | 100764177 |
| 10306520 | 10042936 | 1.78 | 46 | Curative (C) | 2020-03-25 | 2020-03-26 | AVELUMAB + AXITINIB | 02 | null | OBINUTUZUMAB + VENETOCLAX | 101684894 |
| 10306923 | 10042937 | 0 | 64.4 | Curative (C) | 2016-06-05 | 2016-06-05 | Apalutamide | 02 | N | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 101407948 |
| 10307271 | 10042939 | 1.63 | 69.8 | Palliative (P) | 2018-03-18 | 2018-03-25 | Fulvestrant + Ribociclib | 02 | N | RIBOCICLIB | 100694388 |
| 10308206 | 10042941 | 1.62 | 69.9 | Curative (C) | null | 2018-11-09 | NAB PACLITAXEL | 02 | null | CAPECITABINE + CARBOPLATIN | 101841523 |
| 10308425 | 10042943 | 1.82 | 86 | Curative (C) | 2019-10-18 | 2019-10-18 | LENVATINIB | 02 | null | BORTEZOMIB + DARATUMUMAB | 100268086 |
| 10308837 | 10042944 | 0 | 56 | null | 2016-12-28 | 2017-01-03 | Trastuzumab Subcutaneous | 02 | null | OSIMERTINIB | 101130742 |
| 10309527 | 10042945 | 1.56 | 85.3 | Adjuvant (A) | null | 2019-11-17 | Irinotecan + Modified De Gramont | 01 | N | DOXORUBICIN | 100699982 |
| 10309916 | 10042946 | 1.7 | 75.1 | null | 2020-02-21 | 2020-02-22 | Ixazomib + Lenalidomide | 02 | null | RCEOP | 100696826 |
| 10311978 | 10042949 | 1.78 | 63 | Neo-adjuvant (N) | 2019-05-28 | 2019-06-23 | FCR Oral - Cycle 2 onwards | 02 | N | CISPLATIN + PEMETREXED | 100469448 |
| 10319354 | 10042952 | 1.6 | 0 | Palliative (P) | 2017-06-24 | 2017-08-26 | Sorafenib | 02 | N | OFATUMUMAB | 101300741 |
| 10322684 | 10042953 | 1.7 | 78.3 | null | 2022-04-29 | 2022-05-26 | ABVD | 02 | null | LANREOTIDE | 100184092 |